Home Growth Disorders NGENLA
Pfizer

NGENLA

somatrogon-ghla injection, A once-weekly growth hormone treatment for pediatric patients aged 3 years and older with growth hormone deficiency.

About NGENLA

Once-Weekly GH for Pediatric Patients

NGENLA (somatrogon-ghla) is a once-weekly growth hormone injection developed by Pfizer for the treatment of growth hormone deficiency in pediatric patients. It is a long-acting recombinant human growth hormone that utilizes C-terminal peptide technology to extend its half-life for weekly dosing.

  • Once-weekly subcutaneous injection
  • Approved for pediatric patients age 3 and older with GHD
  • Reduces daily injection burden to once weekly
  • Available as a pre-filled pen for ease of use
  • Developed by Pfizer, a trusted name in growth hormone therapy
Pediatric GHD Treatment

NGENLA is indicated for pediatric patients 3 years and older with growth failure due to inadequate secretion of endogenous growth hormone.

1×

Weekly Injection

For children age 3 and older

C-Terminal Peptide Technology
Extended half-life enables once-weekly dosing for pediatric GHD patients
Downloads

Patient & Clinical Resources

Patient Brochure
PDF Document
Back to Growth Disorders
Traveling with your medication? This medication requires refrigeration. Our partner 4AllFamily offers insulin coolers and medical travel cases to keep your medication safe wherever you go.
Shop Now

Questions About NGENLA?

Our clinical pharmacists are here to help patients, caregivers, and providers with enrollment and information about once-weekly growth hormone therapy.

Contact Us (800) 219-5920